SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - FRA:56S1 - FR0013154002 - Common Stock
207.2 EUR
-1.7 (-0.81%)
56S1 gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 20 industry peers in the Life Sciences Tools & Services industry. 56S1 has an average financial health and profitability rating. 56S1 is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
56S1 had positive earnings in the past year.
In the past year 56S1 had a positive cash flow from operations.
56S1 had positive earnings in each of the past 5 years.
In the past 5 years 56S1 always reported a positive cash flow from operatings.
1.2 Ratios
56S1 has a Return On Assets (3.35%) which is comparable to the rest of the industry.
56S1 has a Return On Equity (6.54%) which is in line with its industry peers.
The Return On Invested Capital of 56S1 (5.94%) is comparable to the rest of the industry.
56S1 had an Average Return On Invested Capital over the past 3 years of 10.41%. This is above the industry average of 7.43%.
The last Return On Invested Capital (5.94%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
56S1 has a better Profit Margin (8.96%) than 65.00% of its industry peers.
56S1's Profit Margin has declined in the last couple of years.
With a decent Operating Margin value of 16.63%, 56S1 is doing good in the industry, outperforming 70.00% of the companies in the same industry.
56S1's Operating Margin has declined in the last couple of years.
56S1 has a better Gross Margin (45.64%) than 65.00% of its industry peers.
In the last couple of years the Gross Margin of 56S1 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 56S1 is creating some value.
Compared to 1 year ago, 56S1 has more shares outstanding
Compared to 5 years ago, 56S1 has more shares outstanding
The debt/assets ratio for 56S1 has been reduced compared to a year ago.
2.2 Solvency
56S1 has an Altman-Z score of 4.45. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
56S1's Altman-Z score of 4.45 is amongst the best of the industry. 56S1 outperforms 90.00% of its industry peers.
The Debt to FCF ratio of 56S1 is 6.84, which is on the high side as it means it would take 56S1, 6.84 years of fcf income to pay off all of its debts.
56S1 has a Debt to FCF ratio (6.84) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.50 indicates that 56S1 is not too dependend on debt financing.
56S1 has a Debt to Equity ratio (0.50) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.45 |
ROIC/WACC0.69
WACC8.6%
2.3 Liquidity
56S1 has a Current Ratio of 1.05. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.05, 56S1 is not doing good in the industry: 65.00% of the companies in the same industry are doing better.
A Quick Ratio of 0.50 indicates that 56S1 may have some problems paying its short term obligations.
56S1 has a Quick ratio of 0.50. This is in the lower half of the industry: 56S1 underperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
The earnings per share for 56S1 have decreased strongly by -16.47% in the last year.
56S1 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.19% yearly.
Looking at the last year, 56S1 shows a small growth in Revenue. The Revenue has grown by 7.72% in the last year.
Measured over the past years, 56S1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.05% on average per year.
EPS 1Y (TTM)-16.47%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%153.85%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
The Earnings Per Share is expected to grow by 22.23% on average over the next years. This is a very strong growth
Based on estimates for the next years, 56S1 will show a quite strong growth in Revenue. The Revenue will grow by 10.45% on average per year.
EPS Next Y27.61%
EPS Next 2Y23.83%
EPS Next 3Y23.3%
EPS Next 5Y22.23%
Revenue Next Year9.03%
Revenue Next 2Y9.51%
Revenue Next 3Y10.23%
Revenue Next 5Y10.45%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
56S1 is valuated quite expensively with a Price/Earnings ratio of 59.20.
Compared to the rest of the industry, the Price/Earnings ratio of 56S1 indicates a rather expensive valuation: 56S1 more expensive than 80.00% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.19, 56S1 is valued quite expensively.
56S1 is valuated quite expensively with a Price/Forward Earnings ratio of 38.61.
56S1's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 70.00% of the companies in the same industry.
56S1 is valuated expensively when we compare the Price/Forward Earnings ratio to 22.50, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.2 | ||
| Fwd PE | 38.61 |
4.2 Price Multiples
80.00% of the companies in the same industry are cheaper than 56S1, based on the Enterprise Value to EBITDA ratio.
56S1's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 53.85 | ||
| EV/EBITDA | 27.77 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of 56S1 may justify a higher PE ratio.
56S1's earnings are expected to grow with 23.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.14
PEG (5Y)14.11
EPS Next 2Y23.83%
EPS Next 3Y23.3%
5. Dividend
5.1 Amount
With a yearly dividend of 0.33%, 56S1 is not a good candidate for dividend investing.
56S1's Dividend Yield is comparable with the industry average which is at 0.69.
With a Dividend Yield of 0.33, 56S1 pays less dividend than the S&P500 average, which is at 2.33.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
56S1 pays out 25.41% of its income as dividend. This is a sustainable payout ratio.
56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP25.41%
EPS Next 2Y23.83%
EPS Next 3Y23.3%
FRA:56S1 (10/30/2025, 7:00:00 PM)
207.2
-1.7 (-0.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.17B
Revenue(TTM)2.95B
Net Income(TTM)264.10M
Analysts81.11
Price Target239.46 (15.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.41%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)0%
PT rev (3m)-1.4%
EPS NQ rev (1m)2.45%
EPS NQ rev (3m)2.75%
EPS NY rev (1m)0%
EPS NY rev (3m)2.93%
Revenue NQ rev (1m)-0.63%
Revenue NQ rev (3m)3.91%
Revenue NY rev (1m)-1.33%
Revenue NY rev (3m)0.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.2 | ||
| Fwd PE | 38.61 | ||
| P/S | 6.84 | ||
| P/FCF | 53.85 | ||
| P/OCF | 27.6 | ||
| P/B | 5 | ||
| P/tB | N/A | ||
| EV/EBITDA | 27.77 |
EPS(TTM)3.5
EY1.69%
EPS(NY)5.37
Fwd EY2.59%
FCF(TTM)3.85
FCFY1.86%
OCF(TTM)7.51
OCFY3.62%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)2.14
PEG (5Y)14.11
Graham Number57.15
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 113.12% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.78% | ||
| Profit Quality | 141.8% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.45 |
F-Score8
WACC8.6%
ROIC/WACC0.69
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)-16.47%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%153.85%
EPS Next Y27.61%
EPS Next 2Y23.83%
EPS Next 3Y23.3%
EPS Next 5Y22.23%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
Revenue Next Year9.03%
Revenue Next 2Y9.51%
Revenue Next 3Y10.23%
Revenue Next 5Y10.45%
EBIT growth 1Y25.54%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year92.67%
EBIT Next 3Y37.11%
EBIT Next 5Y27.7%
FCF growth 1Y219.27%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.97%
OCF growth 3Y5.11%
OCF growth 5Y21.32%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 56S1.DE.
What is the valuation status of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a valuation rating of 2 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
Can you provide the profitability details for SARTORIUS STEDIM BIOTECH?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 6 / 10.
What is the financial health of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
The financial health rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10.
How sustainable is the dividend of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
The dividend rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10 and the dividend payout ratio is 25.41%.